Revived Alzheimer’s antibody met with guarded optimism
Biogen’s aducanumab offers the possibility to slow disease progress, but regulators will likely want more convincing evidence
In October 2019, Biogen unexpectedly revived an antibody treatment targeting Alzheimer’s, having abandoned clinical trials the preceding March. The company’s presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in early December therefore became a hotly anticipated opportunity for the community to get a better look at the data and understand Biogen’s decision.
The reception was mostly positive. Biogen will now file for US market approval for its amyloid-targeting antibody, aducanumab, but success is by no means assured.